Todd C. Knepper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Todd C. Knepper has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Howard L. McLeod
Center for Precision Medicine and Functional Genomics, Utah Tech University, St George, UT
22 shared publications Nikhil I. Khushalani
20 shared publicationsEthan S. Sokol
19 shared publications- Garrett M. Frampton
Computational Discovery, Foundation Medicine, Inc., Cambridge, USA
19 shared publications - James A. DeCaprio
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
19 shared publications - Jane L. Messina
Moffitt Cancer Center and Research Institute Tampa Florida USA
19 shared publications
Latest Publications
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500368
Case of KRAS G12C-Mutated AML Treated With Sotorasib
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500368
Case of KRAS G12C-Mutated AML Treated With Sotorasib
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Raw patient and scRNA-seq data
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Raw patient and scRNA-seq data
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort.Supplemental Table 2. List of 80 genes with RNA sequencing coverage.Supplemental Table 3. Demographics of 400 adult ALL cases.Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients.Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients.Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients.Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort.Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients.Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments.Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment.Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort.Supplemental Table 2. List of 80 genes with RNA sequencing coverage.Supplemental Table 3. Demographics of 400 adult ALL cases.Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients.Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients.Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients.Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort.Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients.Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments.Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment.Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort.Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL.Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations.Supplemental Figure 4. Germline testing in the adult ALL cohort.Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL.Supplemental Figure 6. Overall survival in adults with B-ALL.Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy.Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM).Supplemental Figure 9. Expression levels of lineage-specific surface markers.Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM.Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1.Supplemental Figure 12. Clonal dynamics of ALL with MyM.Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22.Supplemental Figure 14. Clonal evolution of B-ALL2.Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy.Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses.Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab.Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab.Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort.Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL.Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations.Supplemental Figure 4. Germline testing in the adult ALL cohort.Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL.Supplemental Figure 6. Overall survival in adults with B-ALL.Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy.Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM).Supplemental Figure 9. Expression levels of lineage-specific surface markers.Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM.Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1.Supplemental Figure 12. Clonal dynamics of ALL with MyM.Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22.Supplemental Figure 14. Clonal evolution of B-ALL2.Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy.Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses.Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab.Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab.Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Raw patient and scRNA-seq data
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Raw patient and scRNA-seq data
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort.Supplemental Table 2. List of 80 genes with RNA sequencing coverage.Supplemental Table 3. Demographics of 400 adult ALL cases.Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients.Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients.Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients.Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort.Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients.Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments.Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment.Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort.Supplemental Table 2. List of 80 genes with RNA sequencing coverage.Supplemental Table 3. Demographics of 400 adult ALL cases.Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients.Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients.Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients.Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort.Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients.Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments.Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment.Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort.Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL.Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations.Supplemental Figure 4. Germline testing in the adult ALL cohort.Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL.Supplemental Figure 6. Overall survival in adults with B-ALL.Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy.Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM).Supplemental Figure 9. Expression levels of lineage-specific surface markers.Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM.Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1.Supplemental Figure 12. Clonal dynamics of ALL with MyM.Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22.Supplemental Figure 14. Clonal evolution of B-ALL2.Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy.Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses.Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab.Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab.Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort.Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL.Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations.Supplemental Figure 4. Germline testing in the adult ALL cohort.Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL.Supplemental Figure 6. Overall survival in adults with B-ALL.Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy.Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM).Supplemental Figure 9. Expression levels of lineage-specific surface markers.Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM.Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1.Supplemental Figure 12. Clonal dynamics of ALL with MyM.Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22.Supplemental Figure 14. Clonal evolution of B-ALL2.Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy.Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses.Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab.Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab.Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.
- Open Access
- 26 December 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (3) , 164-179
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Myeloid neoplasms arise from preexisting clonal hematopoiesis (CH); however, the role of CH in the pathogenesis of acute lymphoblastic leukemia (ALL) is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single-cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of these clones expanded over time to manifest as dominant clones in ALL. Single-cell RNA sequencing revealed upregulation of genes associated with cell survival and resistance to apoptosis in B-ALL with MyM, which responds better to newer immunotherapeutic approaches. These findings define ALL with MyM as a high-risk disease that can arise from antecedent CH and offer new mechanistic insights to develop better therapeutic and preventative strategies. Significance: CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years before diagnosis, and ALL with MyM is enriched with activated T cells that respond to immunotherapies such as blinatumomab. See related commentary by Iacobucci, p. 142.
- 26 December 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (3) , 164-179
Open AccessAcute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Myeloid neoplasms arise from preexisting clonal hematopoiesis (CH); however, the role of CH in the pathogenesis of acute lymphoblastic leukemia (ALL) is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single-cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of these clones expanded over time to manifest as dominant clones in ALL. Single-cell RNA sequencing revealed upregulation of genes associated with cell survival and resistance to apoptosis in B-ALL with MyM, which responds better to newer immunotherapeutic approaches. These findings define ALL with MyM as a high-risk disease that can arise from antecedent CH and offer new mechanistic insights to develop better therapeutic and preventative strategies. Significance: CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years before diagnosis, and ALL with MyM is enriched with activated T cells that respond to immunotherapies such as blinatumomab. See related commentary by Iacobucci, p. 142.
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (8) , 679-680
Pharmacist-Driven Precision Medicine: A Ferry to Cross the Chasm of Interpreting Biomarker Testing Reports
Pharmacists as molecular oncology subspecialists can be integral to the multidisciplinary precision oncology team.
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (8) , 679-680
Pharmacist-Driven Precision Medicine: A Ferry to Cross the Chasm of Interpreting Biomarker Testing Reports
Pharmacists as molecular oncology subspecialists can be integral to the multidisciplinary precision oncology team.
- 20 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (15) , 2701-2705
DPYD Testing: Time to Put Patient Safety First
- 20 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (15) , 2701-2705
DPYD Testing: Time to Put Patient Safety First